Lactacystin
Product Code: AG-CN2-0104
Product Group: Natural Products and Extracts
Supplier: AdipoGen Life Sciences
| Code | Size | Price |
|---|
| AG-CN2-0104-C100 | 100 ug | £80.00 |
Quantity:
| AG-CN2-0104-C200 | 200 ug | £120.00 |
Quantity:
| AG-CN2-0104-C500 | 500 ug | £230.00 |
Quantity:
| AG-CN2-0104-M001 | 1 mg | £390.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
Ambient
Storage:
-20°C
Further Information
Appearance:
White to off-white solid.
CAS:
133343-34-7
EClass:
32160000
Form (Short):
liquid
Handling Advice:
Protect from light.
InChi:
InChI=1S/C15H24N2O7S/c1-6(2)10(19)15(11(20)7(3)12(21)17-15)14(24)25-5-9(13(22)23)16-8(4)18/h6-7,9-11,19-20H,5H2,1-4H3,(H,16,18)(H,17,21)(H,22,23)/t7-,9?,10+,11+,15-/m1/s1
InChiKey:
DAQAKHDKYAWHCG-MJZHQVMOSA-N
Long Description:
Chemical. CAS: 133343-34-7. Formula: C15H24N2O7S. MW: 376.4. Isolated from Streptomyces lactacystinnaeus strain OM-6519. Induces neuritogenesis. Potent and selective irreversible proteasome inhibitor. Specifically inhibits 20S proteasome (MCP; multicatalytic complex). Blocks proteasome activity by targeting the catalytic beta-subunit. Apoptosis inducer. Anticancer compound. Upregulates HSP70 and HSP22. Induces differentiation and inhibits cell cycle progression in several tumor cell lines. Inhibits NF-kappaB activation by inhibiting IkappaB degradation. Cathepsin A inhibitor. beta-Secretase activity inhibitor. Anti-adipogenic.
MDL:
MFCD01076525
Molecular Formula:
C15H24N2O7S
Molecular Weight:
376.4
Package Type:
Vial
Product Description:
Induces neuritogenesis [1, 3]. Potent and selective irreversible proteasome inhibitor. Specifically inhibits 20S proteasome (MCP; multicatalytic complex) [2, 4, 7]. Blocks proteasome activity by targeting the catalytic beta-subunit [5]. Apoptosis inducer [4, 6, 7, 10]. Anticancer compound [6, 10, 13]. Upregulates HSP70 and HSP22 [8]. Induces differentiation and inhibits cell cycle progression in several tumor cell lines [9]. Inhibits NF-kappaB activation by inhibiting IkappaB degradation [11]. Cathepsin A inhibitor [12]. beta-Secretase activity inhibitor [14]. Anti-adipogenic [15, 16]. Autophagy inducer [17].
Purity:
>98% (HPLC)
SMILES:
CC(C)[C@H](O)[C@]1(NC(=O)[C@H](C)[C@@H]1O)C(=O)SC[C@H](NC(C)=O)C(O)=O
Solubility Chemicals:
Soluble in water (10mM), methanol, ethanol, DMSO, pyridine, acetonitrile or dimethyl formamide. Insoluble in hexane, benzene, chloroform or ethyl acetate.
Source / Host:
Isolated from Streptomyces lactacystinnaeus strain OM-6519.
Transportation:
Non-hazardous
UNSPSC Category:
Natural Products/Extracts
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 3 years after receipt when stored at -20°C.
References
Lactacystin, a novel microbial metabolite, induces neuritogenesis of neuroblastoma cells: S. Omura, et al.; J. Antibiot. (Tokyo) 44, 113 (1991) | Inhibition of proteasome activities and subunit-specific amino-terminal threonine modification by lactacystin: G. Fenteany, et al.; Science 268, 726 (1995) | Structure-activity relationships of lactacystin, the first non-protein neurotrophic factor: T. Nagamitsu, et al.; J. Antibiot. (Tokyo) 48, 747 (1995) | Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells: S. Imajoh-Ohmi, et al.; BBRC 217, 1070 (1995) | Lactacystin and clasto-lactacystin beta-lactone modify multiple proteasome beta-subunits and inhibit intracellular protein degradation and major histocompatibility complex class I antigen presentation: A. Craiu, et al.; J. Biol. Chem. 272, 56 (1997) | The proteasome inhibitor lactacystin induces apoptosis and sensitizes chemo- and radioresistant human chronic lymphocytic leukaemia lymphocytes to TNF-alpha-initiated apoptosis: J. Delic, et al.; Br. J. Cancer 77, 1103 (1998) | Lactacystin, proteasome function, and cell fate: G. Fenteany & S.L. Schreiber; J. Biol. Chem. 273, 8545 (1998) (Review) | Proteasome inhibitors MG132 and lactacystin hyperphosphorylate HSF1 and induce hsp70 and hsp27 expression: D. Kim, et al.; BBRC 254, 264 (1999) | Induction of G1 arrest and selective growth inhibition by lactacystin in human umbilical vein endothelial cells: S.I. Kumeda, et al.; Anticancer Res. 19, 3961 (1999) | Lactacystin activates FLICE (caspase 8) protease and induces apoptosis in Fas-resistant adult T-cell leukemia cell lines: Y. Yamada, et al.; Eur. J. Haematol. 64, 315 (2000) | Inhibitory and stimulatory effects of lactacystin on expression of nitric oxide synthase type 2 in brain glial cells. The role of Ikappa B-beta: M. Stasiolek, et al.; J. Biol. Chem. 275, 24847 (2000) | Lactacystin inhibits cathepsin A activity in melanoma cell lines: L. Kozlowski, et al.; Tumour Biol. 22, 211 (2001) | Lactacystin exhibits potent anti-tumor activity in an animal model of malignant glioma when administered via controlled-release polymers: F.G. Legnani, et al.; J. Neurooncol. 77, 225 (2006) | Lactacystin decreases amyloid-beta peptide production by inhibiting beta-secretase activity: P. Kienlen-Campard, et al.; J. Neurosci. Res. 84, 1311 (2006) | Lactacystin inhibits 3T3-L1 adipocyte differentiation through induction of CHOP-10 expression: X. Li, et al.; BBRC 350, 1 (2006) | Inhibition of human preadipocyte proteasomal activity by HIV protease inhibitors or specific inhibitor lactacystin leads to a defect in adipogenesis, which involves matrix metalloproteinase-9: S. De Barros, et al.; J. Pharmacol. Exp. Ther. 320, 291 (2007) | Mechanisms of cross-talk between the ubiquitin-proteasome and autophagy-lysosome systems: V.I. Korolchuk, et al.; FEBS Lett. 584, 1393 (2010) | Remodeling the endoplasmic reticulum proteostasis network restores proteostasis of pathogenic GABAA receptors: Y.-L. Fu, et al.; PLOS One 13, e0207948 (2018)